Highlights newsletter 2
This newsletter presents you the following presentations:
1. Bevacizumab demonstrates benefit as first-line therapy in HER2-positive breast cancer
3. Dual HER2 blockage significantly extends progression-free survival
4. Immediate zoledronic acid use combined with endocrine therapy reduces recurrence and increases survival in postmenopausal early breast cancer
patients
6. Brachytherapy is associated with an increased risk for mastectomy and postoperative side effects